B
Bitterroot Bio
Innovative immunotherapies targeting the root causes of cardiovascular disease through advanced cardio immunology research
About Bitterroot Bio
Bitterroot Bio, operating under the domain brbio.com, is a pioneering startup in the healthcare sector, specifically focusing on the emerging field of cardio-immunology. The company is dedicated to developing innovative immunotherapies to treat cardiovascular diseases. Their primary market is patients suffering from cardiovascular conditions, particularly those related to inflammation and immune response, such as atherosclerosis.
The company's business model revolves around harnessing the power of immunotherapy, a treatment that uses the body's natural defenses to fight diseases. Bitterroot Bio's approach is unique as it targets the root causes of cardiovascular diseases rather than just treating the symptoms. This is achieved by understanding the role of immune cells and immune modulators in the development and progression of these diseases.
Bitterroot Bio generates revenue by developing and delivering these innovative therapies. The company collaborates closely with cardiologists to ensure the safety and efficacy of their treatments, thereby providing a new hope for patients suffering from cardiovascular diseases.
In simple terms, Bitterroot Bio is working on treatments that can help the body's immune system fight off heart diseases. One of their main focuses is atherosclerosis, a disease where fatty deposits build up in the arteries, making it hard for blood to flow. They believe this disease is caused by inflammation and are developing treatments to stop this inflammation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Palo Alto, United States
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 25.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2023 | $145M | $580M | Koch Disruptive Technologies · ARCH Venture Partners · GV · Alexandria Venture Investments | ↗ |
| SPINOUTOther financing | Jan 2021 | $0 | — | Stanford University | — |
Growth signals
Latest recorded traffic for Bitterroot Bio is 2.9K monthly website visits, down 12.1% over the last three months. Bitterroot Bio's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
ARCH Venture Partners
Deerfield
Koch Disruptive Technologies
GV
Alexandria Venture Investments
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bitterroot Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bitterroot Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.